National Cancer Institute (NCI)
14,196
1,409
2,815
8,547
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 65/100
15.8%
2242 terminated/withdrawn out of 14196 trials
79.2%
-7.3% vs industry average
8%
1124 trials in Phase 3/4
51%
4328 of 8547 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (14196)
NCI Childhood Cancer Data Initiative (CCDI) Led Pediatric, Adolescent, and Young Adult Rare Cancer Registry for Very Rare Solid Tumors
Role: lead
Well-Being and Health-Related Quality of Life in Melanoma Patients During COVID-19 Pandemic
Role: collaborator
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
Role: lead
Aerosolized Aldesleukin in Treating Patients With Lung Metastases
Role: collaborator
Clinical Genetics Branch Eligibility Screening Survey
Role: lead
A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis
Role: lead
Tu Salud Si Cuenta Intervention in Increasing Physical Activity and Healthy Eating Among Latino Families
Role: collaborator
Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
Role: lead
Development and Evaluation of a Quantitative HP MRI for Clinical Prostate Cancer Exam
Role: collaborator
Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Malignancies Who Receive CAR T-cell Therapy
Role: lead
Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy
Role: lead
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
Role: lead
LiveWell: An Adapted Dialectical Behavioral Therapy Skills Training Protocol for Patients Living With Metastatic Lung Cancer
Role: collaborator
NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer
Role: collaborator
Ruxolitinib Phosphate in Reducing Fatigue in Patients With Chronic Lymphocytic Leukemia
Role: collaborator
Medical Data Collection of Patients With Head and Neck Cancer Treated With Proton Therapy
Role: collaborator
FITting Non-invasive Tests in Lynch Syndrome Surveillance
Role: collaborator
Imatinib to Increase RUNX1 Activity in Participants With Germline RUNX1 Deficiency
Role: lead
Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors
Role: collaborator
CD22 CAR T-cells to Extend Remission Following Commercial CD19 CAR T-cells in Children, Adolescents, and Adults With Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia
Role: lead